Posterior Reversible Encephalopathy Syndrome Instigated by Off-Label Disulfiram Use for Metastatic Melanoma
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A case report describes posterior reversible encephalopathy syndrome following alcohol-free disulfiram exposure for antineoplastic (metastatic melanoma) purposes.
“Another case report describes the emergence of posterior reversible encephalopathy syndrome following alcohol-free DIS exposure, underscoring the need for consultation-liaison psychiatrists to maintain a high index of suspicion for adverse drug reactions associated with off-label use for antineoplastic (metastatic melanoma) purposes.25”
From Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence (2026) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 20 · Cited by 6
Research works printed but not linked: 20
- [1]Coppens S, Naeije G, Mavroudakis N: Posterior reversible encephalopathy syndrome following disulfiram intoxication. J Neurol 2011; 258(8): 1548– 50. doi: 10.1007/s00415-011-5945-9 21340520 · DOI
- [2]Mishra A, Priyadarshi VM: Posterior Reversible Encephalopathy Syndrome (PRES) Following Disulfiram Intoxication - A Case Report. Indian J Public Health Res Dev 2013; 4(3): 19– 22.
- [3]Lee VH, Wijdicks EF, Manno EM, Rabinstein AA: Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008; 65(2): 205– 10. doi: 10.1001/archneurol.2007.46 18268188 · DOI
- [4]Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA: Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010; 85(5): 427– 32. doi: 10.4065/mcp.2009.0590 20435835 PMC2861971 · DOI
- [5]Ahn KJ, You WJ, Jeong SL,: Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping. Neuroradiology 2004; 46(12): 978– 83. doi: 10.1007/s00234-004-1276-1 15536557 · DOI
- [6]Hobson EV, Craven I, Blank SC: Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int 2012; 32(6): 590– 4. doi: 10.3747/pdi.2012.00152 23212858 PMC3524908 · DOI
- [7]Ehrlich RI, Woolf DC, Kibel DA: Disulfiram reaction in an artist exposed to solvents. Occup Med (Lond) 2012; 62(1): 64– 6. doi: 10.1093/occmed/kqr172 22068046 · DOI
- [8]Watts TE, Pandey RA, Vancil TJ: Fatal fulminant hepatic failure related to the use of disulfiram. J Arc Med Soc 2014; 110(13): 280– 3. 25004669
- [9]Huang J, Campian JL, Gujar AD,: A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. J Neurooncol 2016; 128(2): 259– 66. doi: 10.1007/s11060-016-2104-2 26966095 · DOI · Paper page
- [10]Kulkarni RR, Ramdurg SI, Bairy BK: Disulfiram-induced reversible hypertension: a prospective case series and review of the literature. Indian J Psychol Med 2014; 36(4): 434– 8. doi: 10.4103/0253-7176 25336781 PMC4201801 · DOI
- [11]Volicer L, Nelson KL: Development of reversible hypertension during disulfiram therapy. Arch Intern Med. 1984; 144(6): 1294– 6. 6732388
- [12]Bourdélat-Parks BN, Anderson GM, Donaldson ZR,: Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice. Psychopharmacology. 2005 11; 183(1): 72– 80. doi: 10.1007/s00213-005-0139-8 16163519 · DOI
- [13]Ewing JA, Rouse BA, Mueller RA, Silver D: Can dopamine beta-hydroxylase levels predict adverse reactions to disulfiram? Alcohol Clin Exp Res 1978; 2(1): 93– 4. 345861
- [14]Bertolini F, Sukhatme VP, Bouche G: Drug repurposing in oncology - patient and health systems opportunities. Nat Rev Clin Oncol 2015; 12(12): 732– 42. doi: 10.1038/nrclinonc.2015 26483297 · DOI
- [15]Cen D, Brayton D, Shahandeh B, Meyskens FL Jr, Farmer PJ: Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem 2004; 47(27): 6914– 20. doi: 10.1021/jm049568z 15615540 · DOI
- [16]Yip NC, Fombon IS, Liu P,: Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer 2011; 104(10): 1564– 74. doi: 10.1038/bjc.2011.126 21487404 PMC3101904 · DOI
- [17]Xu B, Wang S, Li R,: Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2. Cell Death Dis 2017; 8(5): e2797. doi: 10.1038/cddis.2017.176 28518151 PMC5520701 · DOI
- [18]Viola-Rhenals M, Patel KR, Jaimes-Santamaria L, Wu G, Liu J, Dou QP: Recent advances in Antabuse (disulfiram): the importance of its metal-binding ability to its anticancer activity. Curr Med Chem 2018; 25(4): 506– 24. doi: 10.2174/0929867324666171023161121 29065820 PMC6873226 · DOI
- [19]Huang J, Chaudhary R, Cohen AL,: A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol 2019; 142(3): 537– 44. 30771200
- [20]De Giorgi V, Grazzini M, Benemei S,: Propranolol for off-label treatment of patients with melanoma: results from a cohort study. JAMA Oncol 2018; 4(2): e172908. doi: 10.1001/jamaoncol.2017.2908 28973254 PMC5838568 · DOI
- Authors
- Beam, D. R., & Knight, J. M.
- Affiliations
- Medical College of Wisconsin (US)
- Corresponding author
- Beam, David R.
- Venue
- Psychosomatics
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 61
- Issue
- 3
- Pages
- 302-306
- ISSN
- 0033-3182 (ISSN-L)
- PMC
- PMC7075719
- OpenAlex
- W2974899763
- Cited by
- 6
- References
- 20
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2020: 1
- FWCI
- 0.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Neurological Complications and Syndromes
- Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- posterior reversible encephalopathy syndrome, disulfiram, off-label drug use, metastatic melanoma, adverse drug reactions
- MeSH terms
- Aged, Disulfiram, Humans, Male, Melanoma, Posterior Leukoencephalopathy Syndrome, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
